The NLRP3 inflammasome has emerged as a major therapeutic target to limit pro-inflammatory IL-1β activity in obesity-associated metabolic disorders (Coll et al, 2022). Here, IL1B is linked to obesity due to melanocortin 4 receptor deficiency.